The role of p53 in determining sensitivity to radiotherapy

By A. Gudkov, E. Komarova. Nature Reviews. Cancer, 2003

607 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Modeling the therapeutic efficacy of p53 restoration in tumors. (2006, background): “By demonstrating how restoration of p53 to p53 null tumors can enhance the therapeutic response to irradiation in tumors, our data also underscore the pivotal role that p53 functionality plays in response to cancer therapies (Brown and Attardi, 2005; Gudkov and Komarova, 2003).”
Alkylating DNA damage stimulates a regulated form of necrotic cell death. (2004, background): “Loss of p53 function is associated with pronounced apoptotic resistance (Vousden and Lu 2002; Gudkov and Komarova 2003).”
Control of apoptosis by p53 (2003, background): “In principle, this may influence the utility of certain chemotherapeutic agents, as many of their dose-limiting side effects arise in tissues having apoptosis as their default p53 response (e.g. intestinal epithelium and the hematopoietic system Gudkov and Komarova, 2003).”
The p53 pathway: positive and negative feedback loops (2005, unknown): “…alkylation of bases, depurination of DNA or reaction with oxidative free radicals all alter the DNA in different ways, and for each damaging agent, a different detection and repair mechanism is employed by the cell (for reviews see Giaccia and Kastan, 1998; Gudkov and Komarova, 2003; Oren, 2003).”